Evaxion announces closing of $10.8 million public offering

$EVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $EVAX alert in real time by email

COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares ("ADSs") and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs.

MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering along with healthcare-focused investment funds. There was also participation from Evaxion's Board of Directors and Management.

The warrants have an exercise price of $2.71 per ADS, are exercisable immediately upon issuance and will expire five years following the date of issuance. Each ADS represents fifty ordinary shares of the company.

Lake Street Capital Markets and Jones acted as the exclusive placement agents for the offering. The gross proceeds to the company from the offering were $10.8 million, before deducting the placement agent's fees and other offering expenses payable by the company. The company intends to use the net proceeds of this offering to advance the company's preclinical and clinical pipeline, and for continuing operating expenses and working capital.

The securities described above were offered pursuant to a registration statement on Form F-1, as amended (File No. 333-283304), which was declared effective by the Securities and Exchange Commission ("SEC") on January 29, 2025. The offering was made only by means of a prospectus forming a part of the effective registration statement relating to the offering.

A final prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained on the SEC's website located at http://www.sec.gov and may also be obtained by contacting Lake Street Capital Markets at Attn: Syndicate Department, 920 Second Avenue South, Suite 700, Minneapolis, MN 55402, by calling (612) 326-1305, or by emailing syndicate@lakestreetcm.com or JonesTrading Institutional Services LLC ("Jones") at Attn: Equity Capital Markets, 325 Hudson Street, 6th Floor, New York, NY 10013, by emailing ecm@jonestrading.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Contact information 

Evaxion Biotech A/S

Mads Kronborg

Vice President, Investor Relations & Communication

+45 53 54 82 96

mak@evaxion.ai

About EVAXION

Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients' lives by providing innovative and targeted treatment options.

Forward-looking statement 

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "target," "believe," "expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate," "continue," "estimate," "plan," "potential," "predict," "project," "will," "can have," "likely," "should," "would," "could," and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 



Primary Logo

Get the next $EVAX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EVAX

DatePrice TargetRatingAnalyst
4/2/2024$8.00Neutral → Buy
Ladenburg Thalmann
2/12/2024$14.00Buy
H.C. Wainwright
More analyst ratings

$EVAX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Evaxion announces business update and full year 2024 financial results

    COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results.Business highlights2024 and the first months of 2025 saw Evaxion make substantial progress in both business development, research and development and financing. Key highlights are listed below.Our transformational partnership with MSD (Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA) on two vaccine candidates for infectious diseases entered in September 2024. The projects are tracking according to the agreed plans towar

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to announce business update and full year 2024 financial results on April 1, 2025

    COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numb

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

    New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EVX-01The trial remains on track for two-year clinical efficacy data readout in the second half of 2025COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. D

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EVAX
SEC Filings

See more

$EVAX
Leadership Updates

Live Leadership Updates

See more
  • Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

    Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Lars Wegner, CEO of Evaxion, said: "As Senior Di

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion Biotech Appoints Lars Holtug to the Board of Directors

    COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors. The vote was held at Evaxion's Annual General Meeting on May 25, 2021. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen M. Boudreau, who chose not to stand for re-election for personal reasons. Marianne Søgaard, Chairwo

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Financials

Live finance-specific insights

See more
  • Evaxion to announce business update and full year 2024 financial results on April 1, 2025

    COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numb

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to announce business update and third quarter 2024 financial results on October 31

    COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.  Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.  To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receiv

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

    COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance v

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more